Cerus Corporation
NASDAQ:CERSMedical - Devices
+$0.08 today
- Market cap
- $391.79M
- Beta
- 1.77
- P/E (TTM)
- -53.8
- EPS (TTM)
- -$0.05
Volume 6.09M
Average 2.33M
CERS Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Cerus CorporationNASDAQ: CERS
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $59.89M rose 38.5% year over year, ahead of the +20.3% change in trailing-twelve-month revenue. Sequentially, it rose 3.7% from the prior quarter. Over 3 fiscal years it compounded at +8.4% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $255M (+23.7%) for the fiscal year ending Dec 2026, a step up from the +14.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $59.89M+3.7% QoQ
- Last fiscal yearDec 2025
- $206.13M+14.3% YoY
- LTMMar 2026
- $222.79M+20.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +38.5% | +19.9% | -18.6 pp |
| 1 year | +14.3% | +23.7% | +9.4 pp |
| 3-year CAGR | +8.4% | +13.8% | +5.5 pp |
| 5-year CAGR | +12.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 206.13M USD
- Year-over-year change
- +14.3%
- 4-year CAGR
- +12.0%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 206.13M | +14.3% |
| FY2024 | 2024-12-31 | 180.27M | +15.3% |
| FY2023 | 2023-12-31 | 156.37M | -3.5% |
| FY2022 | 2022-12-31 | 162.05M | +23.8% |
| FY2021 | 2021-12-31 | 130.86M | — |
Revenue vs competitors
How CERS compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +20.3% is the highest of 4, against a peer median of +0.4%.
- Over three fiscal years its annual growth of +8.4% compares with a peer median of +6.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | €7.43B EUR | -0.2% | +6.0% | |
| LTM Jun 2026 | $1.35B USD | +0.4% | +4.5% | |
| LTM Jun 2026 | $512.28M USD | +8.0% | +49.0% | |
| LTM Mar 2026 | $222.79M USD | +20.3% | +8.4% | |
| Peer median (excluding CERS) | — | +0.4% | +6.0% | |
Competitors are the stored peer set for CERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 130.86M | 162.05M | 156.37M | 180.27M | 206.13M |
| Cost of Revenue | 63.48M | 74.95M | 69.97M | 80.75M | 95.85M |
| Gross Profit | 67.38M | 87.09M | 86.4M | 99.52M | 110.29M |
| Gross Margin | 51.5% | 53.7% | 55.3% | 55.2% | 53.5% |
| Research & Development | 63.69M | 64.11M | 67.64M | 58.91M | 65.72M |
| Selling, General & Admin | 81.29M | 83.34M | 75.52M | 75.89M | 80.91M |
| Operating Expenses | 116.32M | 121.18M | 116.45M | 113.75M | 146.63M |
| Depreciation & Amortization | 3.15M | 2.98M | 2.6M | 1.86M | 2M |
| EBITDA | (45.99M) | (33.52M) | (26.34M) | (10.02M) | (4.94M) |
| EBITDA Margin | -35.1% | -20.7% | -16.8% | -5.6% | -2.4% |
| Operating Income | (48.94M) | (34.08M) | (30.05M) | (14.23M) | (36.35M) |
| Operating Margin | -37.4% | -21.0% | -19.2% | -7.9% | -17.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 4.92M | 5.83M | 8.39M | 8.88M | 8.34M |
| Other Income / Expenses | (5.12M) | (8.26M) | (7.27M) | (6.53M) | 21.06M |
| Income Before Tax | (54.06M) | (42.34M) | (37.32M) | (20.76M) | (15.28M) |
| Pre-Tax Margin | -41.3% | -26.1% | -23.9% | -11.5% | -7.4% |
| Income Tax Expense | 319K | 488K | 325K | 205K | 354K |
| Net Income | (54.37M) | (42.78M) | (37.49M) | (20.92M) | (15.63M) |
| Net Margin | -41.6% | -26.4% | -24.0% | -11.6% | -7.6% |
| EPS (Basic) | (0.32) | (0.24) | (0.21) | (0.11) | (0.08) |
| EPS (Diluted) | (0.32) | (0.24) | (0.21) | (0.11) | (0.08) |
| Weighted Avg Shares | 171.28M | 176.55M | 180.27M | 184.56M | 190.59M |
| Weighted Avg Shares (Diluted) | 171.28M | 176.55M | 180.27M | 184.56M | 190.59M |
Cerus Corporation
NASDAQ:CERS
Intrinsic Alpha fair value
Locked
Current Price
$1.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.